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BDNFNerve injury induces chronic pain and dysregulation of microRNAs in dorsal root ganglia (DRG).
Several downregulated microRNAs are predicted to target Mecp2. MECP2 mutations cause Rett syn-
drome and these patients report decreased pain perception. We confirmed MeCP2 upregulation in
DRG following nerve injury and repression of MeCP2 by miRNAs in vitro. MeCP2 regulates brain-
derived neurotrophic factor (BDNF) and downregulation of MeCP2 by microRNAs decreased Bdnf
in vitro. MeCP2 T158A mice exhibited reduced mechanical sensitivity and Mecp2-null and MeCP2
T158A mice have decreased Bdnf in DRG. MeCP2-mediated regulation of Bdnf in the DRG could
contribute to altered pain sensitivity.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic pain is a prevalent, disabling health condition affecting
more than 100 million people in the United States [1]. Neuropathic
pain caused by injury or dysfunction of the nervous system can
result in peripheral and central sensitization, a state of hyperex-
citability due to reduction in threshold and an amplification in
the responsiveness of nociceptors [2]. Elucidation of signaling
pathways underlying pain hypersensitivity is crucial in improving
our understanding of molecular mechanisms that drive plasticity
in the nervous system promoting the development and mainte-
nance of chronic pain states [3]. Animal models of neuropathic
pain have been pivotal in the exploration of molecular mechanisms
of pain underlying nerve injury [4]. Our miRNA profiling study in
the dorsal root ganglion (DRG) from a nerve injury model identified63 miRNAs differentially regulated compared to sham controls [5].
Bioinformatic prediction indicates 15 downregulated miRNAs are
predicted to target the 30 untranslated region (30UTR) of Mecp2.
Translational repression of MeCP2 mediated by binding of miRNAs
to the 30UTR has been reported [6–10].
MeCP2 binds methylated DNA, and together with co-repressors
or transcriptional activators, mediates downstream changes in
gene expression either directly or by altering chromatin structure
[11,12]. Mutations in the X-linked methyl-CpG-binding protein 2
(MECP2) gene cause Rett syndrome (RTT) [13,14]. Decreased pain
perception is commonly reported in children with RTT [15,16].
The abnormal sensitivity can be as high as 75%, with a potential
relationship between hyposensitivity and specific mutations in
the MECP2 gene [15]. The observations from RTT patients indicate
that decreased functional MeCP2 contributes either directly or
indirectly to reduced pain sensitivity. Since reduced pain sensitiv-
ity observed in RTT patients results from a decrease in functional
MeCP2 protein, we postulated that a decrease in miRNAs that bind
and repress translation of MeCP2 will cause an increase in MeCP2
levels and thus contribute to hypersensitivity.
MeCP2 can mediate downstream transcriptional changes of a
large number of genes and depending on its interacting protein
partners and target genes, MeCP2 can act either as an activator
or repressor [12,17]. MeCP2 is a known regulator of Bdnf [18], a
neurotrophin important in both neuronal development and
peripheral pain mechanisms [19]. BDNF levels in the hypothala-
mus correlated with MeCP2 levels, with lower levels in
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compared to controls [12]. The role of BDNF in both inflammatory
and neuropathic pain is well established [20–23]. Here we investi-
gated if miRNAs downregulated in a rodent model of neuropathic
pain that modulate MeCP2 expression, can induce changes in Bdnf
levels in Neuro-2a cells.
Several mouse models have been generated for investigating
MeCP2 function [24] including alteration of the endogenousMecp2
gene, or introduction of the human MECP2 gene with RTT-
associated mutations. One of the most common mutations
observed in RTT is in amino acid T158, located at the C terminus
of the methyl-CpG binding domain of MeCP2. It has been reported
that 70.6% of patients with this mutation have decreased pain
sensitivity [15]. The phenotype of MeCP2 T158A knockin mice
resembles developmental symptoms found in RTT patients [25].
MeCP2 T158A mice showed a reduction in MeCP2 binding to
methylated DNA and a decrease in MeCP2 protein stability.
Female Mecp2+/ mice and a conditional mouse allele that
expresses 50% of the wild-type level of MeCP2 had a slower
reaction to a conductive heat stimulus [26,27]. We sought to assess
the pain sensitivity of MeCP2 T158A mice as well as expression of
Bdnf to test our hypothesis that MeCP2 plays a role in mediating
pain sensitivity and confirm the functional implication of a
mutation in the methyl binding domain.
Thus here we sought to determine whether miRNAs downregu-
lated after nerve injury regulate MeCP2 and hence modulate Bdnf
expression, contributing to hypersensitivity. We used MeCP2
T158A mice to determine if a point mutation in the methyl binding
domain can attenuate pain sensitivity, and we measured expres-
sion of Bdnf in the DRG from MeCP2 T158A mice and Mecp2-null
mice to determine the regulatory role of MeCP2 on Bdnf in the DRG.
2. Materials and methods
2.1. Cell culture, transfection and luciferase reporter assay
HEK293 and Neuro-2a cells obtained from American Type Cul-
ture Collection (ATCC) were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum at 37 C in 5% CO2. For the reporter assay HEK293 cells were
co-transfected with precursor miRNA or anti-miRNA plasmid
(GeneCopoeia) and luciferase reporter plasmid containing the
30UTR of Mecp2 using Lipofectamine 2000 (Life Technologies) for
48 h. The 8.5 kb 30UTR sequence of Mecp2 was cloned down-
stream of the luciferase reporter gene as 4 constructs of 2 kb
fragment each (GeneCopoeia). The fragment with the miRNA
target sequence of interest (1–2210 bp or 6360–8591 bp) was
co-transfected with corresponding miRNA. The Luc-Pair
Duo-Luciferase assay (GeneCopoeia) was used to measure firefly
and renilla luciferase according to the manufacturer’s instructions.
Firefly luciferase measurements normalized to renilla was used as
a transfection control. For monitoring changes in endogenous
MeCP2, Neuro-2a cells were transfected with precursor miRNA or
anti-miRNA plasmid (GeneCopoeia) using X-tremeGENE HP
(Roche) for 48 h.
2.2. Western blot
Protein from Neuro-2a cells or DRG was isolated using radioim-
munoprecipitation assay buffer (Thermo Scientific). For western
blotting, 20 lg protein lysates were resolved by a 4–12% SDS–PAGE
gel, transferred to the nitrocellulose membrane. The membranes
were probed with MeCP2 antibody [25] at 1:3000 dilution
overnight. Chemiluminescence was detected using FluorChem M
System (Protein Simple). The membrane was also probed with goatanti-rabbit GAPDH-HRP (1:2000 dilution, Santa Cruz) as a loading
control. Quantification was determined using UN-SCAN-IT soft-
ware, MeCP2 expression was normalized to GAPDH.
2.3. Immunocytochemistry
Neuro-2a cells grown on 12mm glass coverslips were trans-
fected with miRNA precursor plasmids with GFP using
X-tremeGENE HP DNA transfection reagent for 48 h. Cells were
fixed in 4% formaldehyde and blocked in 10% normal goat serum
followed by a 3 h incubation in 1:200 anti-MeCP2 antibody
(mentioned above). Anti-Rabbit-IgG Atto 647N secondary antibody
(Sigma) was used for detection of MeCP2. Coverslips were
mounted using Vectashield Mounting Medium with DAPI (Vector
Laboratories). Images were acquired using the 60 objective on
the Olympus 1  81 confocal microscope and Fluoview FV10-
ASW software. Image J was used for quantification. MeCP2 levels
were normalized to DAPI staining of the nucleus. Transfected
(GFP positive) and untransfected (GFP negative) cells were then
compared.
2.4. Quantitative RT-PCR
RNA was purified from Neuro-2a cells, DRG collected from
spared nerve injury (SNI) model, sham control, Mecp2-null, MeCP2
T158A and the corresponding wild-type littermate mice using the
mirVana RNA isolation kit (Life technologies). cDNA synthesis and
qRT-PCR were performed as previously described [28]. The Assay
ID for the Taqman primer probes used were Mm01193535_M1
(Mecp2) and Mm04230607_s1 (Bdnf). Gapdh was used as the nor-
malizer and a t-test was used to perform statistical analysis.
2.5. Animal model of neuropathic pain
The care and use of all mice were approved by the Institutional
Animal Care & Use Committee of Drexel University College of Med-
icine. The SNI model was generated using 8-week old C57BL/6
male mice (Taconic) as previously described [29,30]. Briefly, mice
were anesthetized with isoflurane during surgery. The common
peroneal and tibial nerves of the left paw were ligated, 2–4 mm
of the nerve was sectioned and removed distal to ligation. Sham
mice underwent the same surgical procedures as the SNI group
without ligation and sectioning. Development of mechanical
hypersensitivity was assessed using von Frey filaments [30] and
the Mann–Whitney U test was used to calculate significance. L4
and L5 DRG on the ipsilateral side of surgery were collected
4 weeks post SNI surgery at 12 weeks of age.
2.6. Behavior studies using MeCP2 T158A mice
Male MeCP2 T158A mice and wild-type littermates were pur-
chased from Jackson laboratories (Bar Harbor, Maine). Thermal
and mechanical sensitivity were determined using the Hargreaves’
method [31] and von Frey filaments respectively. Behavior
testing and tissue collection was conducted at 12 weeks of age.
Mann–Whitney U test was used for statistical analysis.
3. Results
3.1. Chronic neuropathic pain induced MeCP2 upregulation in DRG
MeCP2 has been predicted to play a role in pain and modulation
of MeCP2 has been observed in various inflammatory and neuro-
pathic pain models [32,33]. To investigate whether MeCP2 expres-
sion is altered in a neuropathic pain state, we generated an SNI
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Fig. 2. miRNA binding to MeCP2 30UTR. Luciferase assay showing miR-132, miR-
19a, and miR-301 binding to the 30UTR of Mecp2. The luciferase activity was
measured 24 h after miRNA transfection. The data expressed as percentage of
control is the average of 3 independent experiments. Statistically significant
difference from control was calculated using one way ANOVA and Student t-test, p
value **<0.01, ***<0.001.
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4 weeks post-surgery on 12 week old mice is shown in Fig. 1a.
Though there was a trend, the increase in Mecp2 mRNA in DRG
after nerve injury was not significant (Fig. 1b). However, there
was a significant increase in MeCP2 protein in the SNI model
(Fig. 1c). This increased expression of MeCP2 in a neuropathic pain
state could in part be mediated by the reduced expression of miR-
NAs predicted to target Mecp2 in the DRG [5]. We therefore sought
to determine the regulatory role of a selected subset of miRNAs on
MeCP2 expression.
3.2. Confirmation of miRNAs predicted to target Mecp2 30UTR
To experimentally validate the bioinformatics prediction of
miRNAs targeting the Mecp2 30UTR, a luciferase reporter assay
was performed. We tested a subset of miRNAs that were decreased
in the DRG from a nerve injury model based on seed sequence
complementarity, varying positions throughout the 30UTR, the
presence of multiple binding sites, and those not predicted to tar-
get Bdnf mRNA. Reduction in luciferase expression and therefore,
miRNA binding to the Mecp2 30UTR was validated for miR-19a,
miR-301 and miR-132 (Fig. 2), while miR-17 and miR-181 did
not reduce luciferase activity (data not shown).
3.3. MeCP2 expression is modulated by miRNAs
To further evaluate regulation of MeCP2 expression from
miRNA binding, Neuro-2a cells were transfected with precursor
miRNAs or antagomirs that are inhibitors of endogenous miRNAs.
Our data indicate that transfection of Neuro-2a cells with miR-
19a, miR-301 and miR-132 did not decrease Mecp2 mRNA
(Fig. 3a) but reduced MeCP2 protein as shown in western blot
(Fig. 3b) and immunocytochemistry of endogenous MeCP2 in cells
transfected with individual miRNAs (Fig. 3d–f). The antagomirs of
miR-301 and miR-132 increased MeCP2 expression (Fig. 3c). We
did not observe an increase in MeCP2 protein after the transfection
of miR-19a inhibitor which could be due to a low endogenous level of
miR-19a in Neuro-2a cells, the inhibition of which would not lead
to the modulation of MeCP2 expression. Since we did not observe
significant changes in Mecp2 mRNA after over expressing miRNAs,
we conclude that Mecp2 regulation by miRNAs tested is mediated
by translational repression and not through RNA degradation.
3.4. miRNA-mediated decrease of MeCP2 lead to concomitant
reduction in Bdnf
To determine if miRNA mediated regulation of MeCP2 affects
expression of the MeCP2 target genes, we measured Bdnf mRNAB
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Fig. 1. MeCP2 expression in DRG 4 weeks after SNI or sham surgery in 12 weeks old mi
mice were hypersensitive 4 weeks post SNI surgery (n = 10). Significance was determine
showed a trend toward increased expression that was not significant in SNI model com
analysis of MeCP2 expression in DRG showed a significant increase in SNI model, determ
samples (n = 3). Protein expression was normalized to GAPDH.after transfecting Neuro-2a cells with miR-19a, miR-301 and
miR-132. Fig. 4a shows that there was reduction in Bdnf transcripts
after overexpressing miRNAs. Additionally, inhibiting endogenous
miR-132 and miR-301 resulted in increased Bdnf transcript
(Fig. 4b). The miRNAs used in this study were confirmed to target
the Mecp2 30UTR, but are not predicted to bind the Bdnf 30UTR.
Thus, the reduced expression of Bdnf can be a direct consequence
of miRNA mediated regulation of MeCP2.
3.5. MeCP2 T158A mice have reduced mechanical sensitivity
Mice expressing 50% of the wild-type level of MeCP2 and female
Mecp2+/micehave reduced thermal sensitivity [26,34].Wewanted
to further investigate the effect of MeCP2mutations on pain behav-
iorbyassessingnociception inMeCP2T158Amice.Weobserved that
MeCP2 T158A mice have reduced mechanical sensitivity compared
to wild-type littermate control mice (Fig. 5a). We found no signifi-
cant changes in thermal sensitivity as determined by Hargreaves’
method between MeCP2 T158A and wild-type littermate control
mice (data not shown). These results indicate a role for MeCP2 in
mediating mechanical sensitivity.
3.6. Bdnf is downregulated in the DRG of Mecp2-null mice and MeCP2
T158A mice
Several studies using mouse models have shown a direct corre-
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Fig. 3. Regulation of MeCP2 by miRNAs. (A) Taqman analysis of Mecp2 in Neuro-2a cells 48 h after miRNA transfection showed no significant reduction in mRNA (n = 3). (B)
Western blot analysis after transfection of Neuro-2a cells with miR-301, miR-132 and miR-19a significantly reduced MeCP2 protein (n = 3). (C) MeCP2 expression increased
when cells were transfected with anti-miR (miRNA inhibitors) for miR-301 and miR-132; (n = 3, representative blot shown). (D and E) Immunocytochemisty and
quantification for MeCP2 in Neuro-2a cells transfected with miR-132. (F and G) Immunocytochemistry and quantification for MeCP2 in Neuro-2a cells transfected with
miR-19a. (H and I) Immunocytochemistry and quantification for MeCP2 in Neuro-2a cells transfected with miR-301. MeCP2 levels were normalized to DAPI staining of the
nucleus and the graph represents MeCP2 expression relative to untransfected cells. Representative images are shown, n = 3. Significance was determined using Student t-test,
p value *<0.05, **<0.001 ***<0.001.
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Fig. 4. MeCP2 mediated changes in Bdnf transcripts. (A) miRNA-mediated reduction of MeCP2 expression decreased Bdnf mRNA in Neuro-2a cells 48 h after miRNA
transfection as determined by Taqman analysis. (B) Antagomirs, inhibitors of endogenous miRNAs, increased Bdnf mRNA. Gapdh was used as the normalizer, n = 3.
Significance determined using Student t-test, p value *<0.05, **<0.001.
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Fig. 5. MeCP2 T158A knockin mice have decreased mechanical sensitivity and lower Bdnf. (A) Mechanical sensitivity measured by von Frey filaments showed an increase in
withdrawal threshold in 12 weeks old MeCP2 T158A mice, indicating hyposensitivity compared to wild-type littermate controls (n = 5 for MeCP2 T158A mice and n = 7 for
wild-type littermate). Statistically significant difference was determined using the Mann–Whitney U test; there was a significant reduction in withdrawal threshold in the
ipsilateral paw p value *<0.02. (B) DRG from Mecp2-null mice and (C) MeCP2 T158A mice has significantly lower Bdnf mRNA compared to wild-type littermates, (n = 6). (D)
Bdnf was also lower in MeCP2 T158A mice compared to wild-type littermates after SNI surgery. Significance determined using Student t-test, p value *<0.05 (n = 3 for both
MeCP2 T158A mice and wild-type littermate).
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DRG from Mecp2-null mice. Fig. 5b shows a reduction in Bdnf
mRNA levels inMecp2-null mice compared to control. Thus MeCP2
mediated regulation of Bdnf expression in DRG appears to be sim-
ilar to that observed in brain. We then investigated Bdnf levels in
DRG from MeCP2 T158A mice to determine if a loss of function
mutation would yield a similar result (Fig. 5c). We observed a
decrease in Bdnf mRNA in the DRG of MeCP2 T158A mice as was
previously reported in the brain [25]. These results indicate that
in DRG, the role of MeCP2 as an activator is important for preciseregulation of Bdnf and alteration of Bdnf in DRG may be a con-
tributing factor leading to aberrant pain sensitivity in RTT.
3.7. Bdnf is decreased in MeCP2 T158A SNI model compared to
wild-type SNI model mice
To determine how changes in MeCP2 in the DRG affect pain
behavior, we generated an SNI model using MeCP2 T158A mice
and wild-type littermate controls. Unfortunately, conducting
mechanical and thermal sensitivity assessment post-SNI surgery
738 M.T. Manners et al. / FEBS Open Bio 5 (2015) 733–740was not possible in the MeCP2 T158A mouse; post-surgical over
grooming behavior resulted in injuries compared to wild-type
littermates. We collected the DRG from MeCP2 T158A mice
4-weeks post SNI and from wild-type SNI mice, and measured Bdnf
transcripts. After nerve injury, MeCP2 T158A mice have decreased
Bdnf compared to wild-type littermate control mice (Fig. 5d). Bdnf
levels did not differ significantly between SNI and sham MeCP2
T158A mice (data not shown). This suggests that in the absence
of fully functional MeCP2, the upregulation of Bdnf is impaired
even after nerve injury, again suggesting the regulatory role of
MeCP2 on Bdnf.
4. Discussion
The role of MeCP2 in the development and function of the cen-
tral nervous system is well established and neuronal dysfunction
contributes to symptoms associated with RTT [14,35]. Previous
studies investigating the role of MeCP2 in pain have shown differ-
ences in expression pattern of MeCP2 in DRG and spinal cord from
various rodent models of pain. An increase in MeCP2 has been
associated with the development of neuropathic pain in the
chronic constriction injury model in rats 14 days after injury
[36]. MeCP2 is known to play an important role in signaling in
the superficial dorsal horn upon induction of peripheral inflamma-
tion by injecting complete Freund’s adjuvant (CFA) in rat ankle
joint. This study showed that phosphorylation of MeCP2 led to
the release of DNA-bound MeCP2, relieving the repression on a
few MeCP2 target genes in lamina I neurons. These genes were
upregulated rapidly in this model of inflammatory pain [37].
MeCP2 expression was increased in the superficial dorsal horn
7 days following CFA injection in the ankle joint but decreased
7 days following SNI [38]. This study also showed that MeCP2
levels were decreased in activating transcription factor 3 (ATF3)-
positive neurons in DRG after SNI [38]. Another report showed
an increase inMecp2 transcripts in the spinal cord 2 h after periph-
eral injection of formalin [9]. Upregulation of MeCP2 in the central
nucleus of the amygdala was reported in the CFA model [39].
Differences in models, tissues, and time points can influence gene
expression and so we performed qPCR and western blot analysis
for MeCP2 using DRG from a mouse SNI model of neuropathic pain
4 weeks after surgery. We observed a significant increase of MeCP2
protein in DRG.
MeCP2 can regulate microRNAs (miRNAs) [40] and dysregula-
tion of miRNAs was observed in the cerebella of Mecp2-null mice
[41]. miRNA-mediated alteration of MeCP2 was reported to alter
pain threshold in wild-type mice. miR-124a was downregulated
in spinal cord after peripheral noxious stimulation with formalin
and this was associated with an increase inMecp2mRNA [9]. Intra-
venous administration of a miRNA-124a inhibitor enhanced the
nociceptive behavior and miRNA-124a mimic significantly reduced
formalin-induced inflammatory pain. In addition to confirming
thatMecp2 is a target for miR-124a, this study showed administra-
tion of miR-124a mimic induced a decrease in Mecp2 mRNA and
miR-124a inhibitor enhanced MeCP2 levels in the spinal cord [9].
In another study, intrathecal miR-124 treatment reversed persis-
tent hyperalgesia induced by carrageenan and prevented the
development of mechanical allodynia in the SNI model of chronic
neuropathic pain [42]. Thus future studies investigating the role
of miRNAs validated to target Mecp2 will be beneficial in confirm-
ing their role in pain.
Our previous study investigating miRNA changes in DRG identi-
fied several miRNAs predicted to target Mecp2 30UTR. The miRNAs
were downregulated after nerve injury and because of the
expected inverse correlation in expression between miRNAs and
genes they regulate, we selected a subset of 5 miRNAs for further
studies. Of these, miR-19a, miR-301 and miR-132 were confirmedto bind and regulate Mecp2 by translational repression. miR-132 is
a previously validated miRNA for MeCP2 [6] and we included it as a
positive control. This reduction of MeCP2 protein resulted in
decreased Bdnf, indicating that activation by MeCP2 is an impor-
tant mechanism of regulation for normal expression of BDNF.
Our findings that inhibition of miRNA-mediated repression
increased MeCP2 and Bdnf is similar to what was reported for
miR-132 in cultured rat neurons [6].
Alterations in BDNF expression is a common phenomenon in
both RTT and pain states, albeit in reverse direction. BDNF is an
important modulator of sensory neurotransmission in nociceptive
pathways both at spinal and supraspinal levels and has an impor-
tant role in the development of central sensitization that underlies
many forms of hyperalgesia [19]. Many of the biological effects of
BDNF are mediated by the high affinity postsynaptic receptor Tro-
pomyosin receptor kinase B (TrkB). TrkB signaling contributes to
both the induction and maintenance of injury induced persistent
pain and Trk inhibitors have been developed for the treatment of
pain [43]. In addition to correlation of BDNF levels in the hypotha-
lamus with MeCP2 levels, with lower levels inMecp2-null mice and
higher levels in MECP2 overexpressing mice compared to controls
[12], disruption of total BDNF levels and secretion in Mecp2-null
neurons indicate that functional MeCP2 is important for BDNF
expression [44]. BDNF-related therapies have shown a reversal of
cardiorespiratory deficits in Mecp2-null mice and is being pursued
for the amelioration of RTT-like neurological symptoms in mouse
models [18]. Our qPCR studies showed that Bdnf levels in the
DRG were downregulated in both Mecp2-null and MeCP2 T158A
mice. Thus the reduction in endogenous Bdnf could be one of the
contributing factors leading to decreased pain sensitivity. After
SNI surgery, lower levels of Bdnf in MeCP2 T158A mice compared
to wild-type mice further indicates that increased Bdnf in the
DRG after nerve injury is in part mediated by MeCP2. A recent
study investigating the role of MeCP2 in pain regulation and mor-
phine reward showed that MeCP2 and histone dimethyltransferase
G9a induce a transcriptional de-repression of Bdnf in central
nucleus of the amygdala, promoting pain behavior through BDNF
upregulation [39]. Thus in addition to direct activation of Bdnf,
MeCP2 in its role as a transcriptional repressor of G9a, further
enhance BDNF levels in chronic pain.
Our studies showed that mice with the loss of function muta-
tion, T158, have reduced mechanical sensitivity compared to
wild-type littermates. Mecp2Flox/y mice expressing 50% of the
wild-type level of MeCP2 and female Mecp2+/ mice have reduced
thermal sensitivity in a hot plate test [26,34] but there are no
reports to date investigating their mechanical sensitivity. Our
assessment of thermally induced nociception using the Harg-
reaves’ method showed no differences in MeCP2 T158A mice and
wild-type littermates. Differences in the thermal sensitivity could
be due to the specific mutation of MeCP2 or the method of measur-
ing thermal sensitivity. Since BDNF release in dorsal horn in neuro-
pathic pain model is associated with thermal hyperalgesia [45,46],
we postulate that other modes of action may be playing a role in
mediating mechanical sensitivity in T158A mice. Studies investi-
gating function of DRG neurons in naïve animals have shown that
delivering BDNF directly to DRGs induced mechanical allodynia.
Conversely, after nerve injury direct administration of anti-BDNF
antibody to injured DRG attenuated mechanical allodynia [47].
MeCP2 and BDNF are expressed in microglia and astrocytes in
addition to neurons and additional studies are needed to deter-
mine the contribution of these different cell types in modulating
aberrant pain sensation in MeCP2 T158A mice. A recent study
investigated the role of miR-183, a miRNA that was significantly
downregulated in the ipsilateral L5 DRG after SNL [48]. Intrathecal
administration of miR-183 attenuated mechanical allodynia and
this was associated with the downregulation of BDNF transcripts
M.T. Manners et al. / FEBS Open Bio 5 (2015) 733–740 739in DRG [48]. This study demonstrated that downregulation of
BDNF in DRG was correlated with attenuated mechanical allodynia
in SNL model of neuropathic pain. Our data shows that mutations
in Mecp2 can reduce mechanical pain sensitivity. Since MeCP2 can
mediate downstream transcriptional changes of a large number of
genes, we cannot rule out the contribution of other dysregulated
genes (due to T158A mutation in methyl binding domain of
MeCP2) to aberrant pain sensitivity in MeCP2 T158A mice.
In conclusion, our results indicate that miRNA-mediated regula-
tion of MeCP2 can contribute to the mechanical hypersensitivity
observed in neuropathic pain models by altering BDNF in the DRG.
Neuropathic pain induces MeCP2 and BDNF expression in the
DRG; conversely, RTT mouse models lacking or expressing reduced
levels of MeCP2 have decreased Bdnf that can contribute to
mechanical hyposensitivity. Further investigations including
in vivo delivery of miRNAs targeting Mecp2 followed by character-
ization of pain behavior and investigation of MeCP2 expression and
downstream targets in naïve mice, RTT and pain models can pro-
vide insights on therapeutic options for both pain and RTT.Author contributions
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